HHS Awards Up to $4.9 Million to Prepare First U.S. Ibogaine PTSD Studies, for a Drug That Is Still Illegal
Kennedy promises a 'record drug approval process,' while the funding itself pays for groundwork rather than patient research.

Reporting (Associated Press, Nov. 12, 2026): The Associated Press reported that Health Secretary Robert F. Kennedy Jr. announced his department is awarding up to $4.9 million to prepare for the first U.S. studies of ibogaine for post-traumatic stress disorder. AP reported the money will not go directly to patient research but to groundwork to manufacture, dose and design studies. AP described ibogaine as a drug that can cause intense hallucinations, nausea, vomiting, tremors and sometimes deadly irregular heart rhythms, and said it is currently illegal in the same ultra-restrictive class as LSD and ecstasy. Kennedy said the government will receive data and treatment guidance from Beond Inc., a Texas company that has treated more than 3,000 patients with ibogaine in Mexico, and said, "We're going to have, I think, a record drug approval process." Veterans Affairs Secretary Doug Collins said the effort would focus first on safety and "best-in-class research." Source: "Federal funding for new research on controversial psychedelic drug ibogaine," Associated Press via WPXI, https://www.wpxi.com/news/health/trump-administration/YLUZ5D457YZZZOOTP63YE2OB7Y/ WTF Political Rant opinion: Veterans with PTSD deserve urgency, and serious research on a drug many of them are already traveling abroad to try is reasonable. But a promise of a record approval process attached to a drug with documented heart risks should make everyone careful, whichever party likes the idea. The public is also entitled to see the terms of any arrangement under which a company that treats patients supplies the data the government will rely on. That is a question, not an accusation, and the answer should be public. Speed is fine. Skipping safety is not, and sound science should be able to survive both scrutiny and the stopwatch. Discussion question: How fast is too fast for a federal approval process on a drug with documented heart risks, when the patients are veterans in crisis?
